Nan Shan Life Insurance Co. Ltd. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 272,412 shares of the life sciences company’s stock after purchasing an additional 12,646 shares during the period. Illumina makes up 2.1% of Nan Shan Life Insurance Co. Ltd.’s holdings, making the stock its 10th largest position. Nan Shan Life Insurance Co. Ltd.’s holdings in Illumina were worth $100,792,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of ILMN. Ownership Capital B.V. acquired a new stake in Illumina in the 4th quarter valued at approximately $43,794,000. First Trust Advisors LP grew its holdings in Illumina by 125.2% in the 3rd quarter. First Trust Advisors LP now owns 589,717 shares of the life sciences company’s stock valued at $182,270,000 after buying an additional 327,887 shares during the last quarter. Harding Loevner LP grew its holdings in Illumina by 28.0% in the 3rd quarter. Harding Loevner LP now owns 1,474,086 shares of the life sciences company’s stock valued at $455,611,000 after buying an additional 322,674 shares during the last quarter. Sarasin & Partners LLP acquired a new stake in Illumina in the 3rd quarter valued at approximately $54,581,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Illumina by 155.2% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 280,523 shares of the life sciences company’s stock valued at $86,704,000 after buying an additional 170,600 shares during the last quarter. 89.97% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have issued reports on the company. SVB Leerink raised their target price on Illumina from $360.00 to $470.00 and gave the company an “outperform” rating in a report on Friday, February 12th. Argus decreased their price objective on Illumina from $380.00 to $355.00 in a report on Tuesday, December 1st. BTIG Research lifted their price objective on Illumina from $410.00 to $570.00 and gave the stock a “buy” rating in a report on Tuesday, February 16th. Piper Sandler lifted their price objective on Illumina from $415.00 to $510.00 and gave the stock an “overweight” rating in a report on Friday, February 12th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their price objective on Illumina from $330.00 to $335.00 in a report on Wednesday, December 16th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. Illumina currently has an average rating of “Hold” and a consensus price target of $364.60.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 11th. The life sciences company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. Illumina had a net margin of 19.70% and a return on equity of 15.93%. On average, equities research analysts anticipate that Illumina, Inc. will post 4.39 EPS for the current fiscal year.
In other news, SVP Susan H. Tousi sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 20th. The shares were sold at an average price of $400.00, for a total value of $1,000,000.00. Following the transaction, the senior vice president now owns 40,447 shares of the company’s stock, valued at approximately $16,178,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Susan H. Tousi sold 200 shares of the firm’s stock in a transaction dated Friday, December 4th. The shares were sold at an average price of $350.00, for a total transaction of $70,000.00. Following the completion of the transaction, the senior vice president now directly owns 43,547 shares in the company, valued at approximately $15,241,450. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,619 shares of company stock worth $11,528,257. Insiders own 0.38% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Further Reading: What is the price-to-earnings growth (PEG) ratio?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.